Treating cisplatin-resistant ovarian cancer cells with HO-4200 and H-4318 decreases the level of STAT3 target proteins: c-myc, Bcl-2, Bcl-xl, survivin and cyclin D1/D2, giving rise to inhibition of cell survival and induction of apoptosis. The gene discussed is BCL2; the disease is ovarian cancer.